{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:27:19Z","timestamp":1768264039981,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00275","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T08:11:29Z","timestamp":1585642289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Short-Term Efficacy and Tolerability of Paroxetine Versus Placebo for Panic Disorder: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"11","author":[{"given":"Beilin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lexiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiguo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaokuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"B1","first-page":"1","article-title":"Practice guideline for treatment of patients with panic disorder. second edition","volume":"166","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/YIC.0b013e32835a5d2e","article-title":"Newer antidepressants and panic disorder: a meta-analysis","volume":"28","author":"Andrisano","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.4088\/jcp.v60n1205","article-title":"Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder","volume":"60","author":"Bakker","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1176\/ajp.155.1.36","article-title":"Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder","volume":"155","author":"Ballenger","year":"1998","journal-title":"Am. J.Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00004850-200511000-00001","article-title":"Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740","volume":"20","author":"Bergink","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010676.pub2","article-title":"Antidepressants versus placebo for panic disorder in adults","volume":"4","author":"Bighelli","year":"2018","journal-title":"Cochrane. Database Syst. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1586\/14737175.4.2.191","article-title":"Paroxetine in panic disorder: clinical management and long-term follow-up","volume":"4","author":"Dannon","year":"2004","journal-title":"Expert. Rev. Neurother."},{"key":"B8","unstructured":"A double-blind, multicentered, flexible-dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder1994"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013348","article-title":"Efficiency of physical therapy on postural imbalance after stroke: study protocol for a systematic review and meta-analysis","volume":"7","author":"Hugues","year":"2017","journal-title":"BMJ Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0924-977X(95)90629-R","article-title":"Paroxetine, clomipramine and placebo in the treatment of panic disorder","volume":"5","author":"Judge","year":"1995","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1192\/bjp.bp.107.039966","article-title":"Prevalence of common mental disorders in general practice attendees across Europe","volume":"192","author":"King","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-0447.1997.tb00388.x","article-title":"A comparison of paroxetine,clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta. Psychiatr. Scand."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00213-007-0821-0","article-title":"A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder","volume":"194","author":"Pollack","year":"2007","journal-title":"Psychopharmacology(Berl)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/da.20218","article-title":"A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder","volume":"24","author":"Pollack","year":"2007","journal-title":"Depress Anxiety"},{"key":"B17","unstructured":"A double-blind, placebo-controlled, flexible-dosing trial to evaluate the efficacy of controlled-release paroxetine in the treatment of panic disorder\n            SheehanD. V.\n            BurnhamD. B.\n            IyengarM. K.\n            PereraP.\n          2005"},{"key":"B18","unstructured":"A double-blind, placebo-controlled, flexible-dosing trial to evaluate the efficacy of controlled-release paroxetine in the treatment of panic disorder\n            SheehanD. V.\n            BurnhamD. B.\n            IyengarM. K.\n            PereraP.\n          2005"},{"key":"B19","unstructured":"A double-blind, placebo-controlled, flexible-dosing trial to evaluate the efficacy of modified-release paroxetine in the treatment of panic disorder\n            SheehanD. V.\n            BurnhamD. B.\n            IyengarM. K.\n            PereraP.\n          2005"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222288","article-title":"Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis","volume":"14","author":"Shi","year":"2019","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/9780470712184.ch10","article-title":"Addressing Reporting Biases","volume-title":"The Cochrane Handbook for Systematic Reviews of Interventions","author":"Sterne","year":"2008"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106337","article-title":"The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales","volume":"9","author":"Sugarman","year":"2014","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejphar.2019.04.003","article-title":"The effects of probiotic and synbiotic supplementation on inflammatory markers among patients with diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"852","author":"Tabrizi","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"B24","first-page":"1592","article-title":"Panic disorder and antidepressants","volume":"59","author":"Tsuboi","year":"2001","journal-title":"Nihon. Rinsho."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T08:11:35Z","timestamp":1585642295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":24,"alternative-id":["10.3389\/fphar.2020.00275"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00275","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"article-number":"275"}}